Taylor & Francis Group
suppl_data.docx (67.66 kB)

fon-2021-1417_supplementary data.docx

Download (67.66 kB)
posted on 2022-01-25, 10:06 authored by Nathalie Waser, Lien VoLien Vo, Mike McKenna, John Penrod, Sarah Goring

Table S1. PRISMA checklist

Table S2. MEDLINE search strategy.

Table S3. EMBASE search strategy

Table S4. Proportion of patients by treatment modality (without timing) in resected, stages I-III NSCLC

Table S5. Internal and external Validity – assessment of generalizability of study population.


Aim: The aim of this systematic literature review was to describe treatment patterns in non-metastatic NSCLC. Methods: A search was conducted in MEDLINE and EMBASE. Eligible studies were multi-centered (>50 patients) and conducted after 2000 in North America, Europe and Asia. Results: Twenty studies met the eligibility criteria. Based on US and Canadian studies in the resectable population, the proportion of patients who received neoadjuvant chemotherapy/chemoradiotherapy and adjuvant chemotherapy/chemoradiotherapy increased with increasing stage (i.e. <3% in stage I to about 40% in stage III; and 15% in stage I to 30% in stage III, respectively). Within the resectable population, the breakdown between bimodal and trimodal therapy was variable, suggesting that clinical practice is not uniform. Conclusion: Overall, studies were heterogeneous precluding data extrapolation across regions. Despite heterogeneity and limited evidence, this review suggested an increase in neoadjuvant and adjuvant chemotherapy with increasing stage, generally in line with treatment guidelines.


Bristol-Myers Squibb